Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-88549968
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
JNJ-88549968 is a novel, first-in-class bispecific T-cell redirecting antibody developed for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasms (MPNs), including essential thrombocythemia and primary myelofibrosis. The drug works by simultaneously binding to the mutated form of calreticulin (CALRmut) on cancer cells and the CD3 antigen on T lymphocytes, thereby redirecting and activating T cells to selectively target and destroy CALRmut-expressing malignant cells. This mechanism aims to enhance immune-mediated cytotoxicity against MPN clones while sparing healthy wild-type cells. JNJ-88549968 is administered as a subcutaneous injection and is currently in Phase 1 clinical trials[1][2][3][4][5][6][7][8].
- Other names
- anti-CALRmut/anti-CD3 bispecific antibody
02
Targets
CALR mutant C-terminus (Mutant calreticulin C-terminus)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on JNJ-88549968.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-88549968.